TME PHARM.CONF.IPO EO 1- (0N6A) - Total Liabilities
Based on the latest financial reports, TME PHARM.CONF.IPO EO 1- (0N6A) has total liabilities worth €3.72 Million EUR (≈ $4.35 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 0N6A cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
TME PHARM.CONF.IPO EO 1- - Total Liabilities Trend (2021–2025)
This chart illustrates how TME PHARM.CONF.IPO EO 1-'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of TME PHARM.CONF.IPO EO 1-.
TME PHARM.CONF.IPO EO 1- Competitors by Total Liabilities
The table below lists competitors of TME PHARM.CONF.IPO EO 1- ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Panda Financial Holding Corp Ltd
SHG:600599
|
China | CN¥210.17 Million |
|
KAP AG
F:IUR
|
Germany | €150.76 Million |
|
Oakley Capital Investments Limited
LSE:OCI
|
UK | GBX227.55 Million |
|
Revolver Resources Holdings Ltd
AU:RRR
|
Australia | AU$5.46 Million |
|
ICG Enterprise Trust PLC
LSE:ICGT
|
UK | GBX71.65 Million |
|
Txcom SA
PA:ALTXC
|
France | €1.29 Million |
|
Centrex Ltd
AU:CXM
|
Australia | AU$34.09 Million |
|
mVISE AG
XETRA:C1V
|
Germany | €6.96 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down TME PHARM.CONF.IPO EO 1-'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See TME PHARM.CONF.IPO EO 1- net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TME PHARM.CONF.IPO EO 1-'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TME PHARM.CONF.IPO EO 1- (2021–2025)
The table below shows the annual total liabilities of TME PHARM.CONF.IPO EO 1- from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €3.72 Million ≈ $4.35 Million |
+107.48% |
| 2024-12-31 | €1.79 Million ≈ $2.10 Million |
-35.66% |
| 2023-12-31 | €2.79 Million ≈ $3.26 Million |
-57.24% |
| 2022-12-31 | €6.51 Million ≈ $7.61 Million |
+23.68% |
| 2021-12-31 | €5.27 Million ≈ $6.16 Million |
-- |
About TME PHARM.CONF.IPO EO 1-
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indicatio… Read more